Literature DB >> 7190568

Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy.

M Higi, N Niederle, W Bierbaum, C G Schmidt, S Seeber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7190568     DOI： 10.1007/bf00411281

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  7 in total

1.  Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.

Authors:  T S Herman; L H Einhorn; S E Jones; C Nagy; A B Chester; J C Dean; B Furnas; S D Williams; S A Leigh; R T Dorr; T E Moon
Journal:  N Engl J Med       Date:  1979-06-07       Impact factor: 91.245

2.  Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.

Authors:  C Morran; D C Smith; D A Anderson; C S McArdle
Journal:  Br Med J       Date:  1979-05-19

3.  Controlled clinical studies of orally administered antiemetic drugs.

Authors:  C G Moertel; R J Reitemeier
Journal:  Gastroenterology       Date:  1969-09       Impact factor: 22.682

4.  Adverse reactions to marihuana. Classification and suggested treatment.

Authors:  A T Weil
Journal:  N Engl J Med       Date:  1970-04-30       Impact factor: 91.245

5.  Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.

Authors:  S E Sallan; N E Zinberg; E Frei
Journal:  N Engl J Med       Date:  1975-10-16       Impact factor: 91.245

6.  A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum(II) in man.

Authors:  T Kahn; E G Elias; G R Mason
Journal:  Cancer Treat Rep       Date:  1978-07

7.  Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives.

Authors:  J A Talbott; J W Teague
Journal:  JAMA       Date:  1969-10-13       Impact factor: 56.272
  7 in total
  7 in total

1.  An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer.

Authors:  A Kennett; J Hardy; S Shah; R A'Hern
Journal:  Support Care Cancer       Date:  2005-02-08       Impact factor: 3.603

2.  Combination chemotherapy with ifosfamide and cis-dichlorodiammineplatinum (II) in advanced malignant melanoma.

Authors:  R Becher; S Seeber; C G Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

3.  [Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cis-dichlorodiammineplatinum (II) in non-seminomatous testicular cancer. I. Results of a prospective randomized phase III-study with 71 patients with disseminated disease (stage IV) (author's transl)].

Authors:  M E Scheulen; M Higi; R B Schilcher; C R Meier; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1980-08-15

4.  [Chemotherapy with cisplatin-bleomycin and subsequent radiotherapy in advanced head and neck tumors].

Authors:  A Schmieder; H Jacobs; H Maurer; H Pfeifer
Journal:  Klin Wochenschr       Date:  1984-01-02

5.  Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy.

Authors:  Ean-Jeong Seo; Thomas Efferth
Journal:  Oncotarget       Date:  2016-03-29

6.  Methotrimeprazine versus haloperidol in palliative care patients with cancer-related nausea: a randomised, double-blind controlled trial.

Authors:  Janet Rea Hardy; Helen Skerman; Jennifer Philip; Phillip Good; David C Currow; Geoffrey Mitchell; Patsy Yates
Journal:  BMJ Open       Date:  2019-09-12       Impact factor: 2.692

7.  Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review.

Authors:  Isabel Dietz; Andrea Schmitz; Ingrid Lampey; Christian Schulz
Journal:  BMC Palliat Care       Date:  2013-01-19       Impact factor: 3.234
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.